Danube is a biopharmaceutical company focused on eye disease-dedicated to the discovery and development of breakthrough treatments that are derived and driven by our understanding of how the eye works, and how its normal physiology and anatomy break down. Since its founding in 2006, Danube has assembled an experienced and innovative senior management team, a world class Scientific Advisory Board, and a compelling pipeline of lead drug candidates. Our single, simple corporate vision is to improve and maintain sight.

Danube is a company of today, with a vision of tomorrow.